Botuo Bio’s 2025 Annual Performance Quick Report Announcement

SZSIFeb 28 00:00 · Announcements

Biotop Biotechnology (688767.SH) Earnings Flash: Net profit attributable to shareholders in 2025 was RMB 46.7957 million, a year-on-year decrease of 72.39%.

Gelonghui, February 27th | Botuoshengwu (688767.SH) announced its 2025 annual earnings report. During the reporting period, the company achieved total operating revenue of 448 million yuan, representing a year-on-year decrease of 19.85%; operating profit reached 50.0538 million yuan, marking a year-on-year decline of 74.12%; net profit attributable to the parent company’s owners amounted to 46.7957 million yuan, reflecting a year-on-year reduction of 72.39%; net profit attributable to the parent company’s owners after excluding non-recurring gains and losses stood at 24.9815 million yuan, showing a year-on-year drop of 79.06%. The main factors affecting operating performance were: (1) Operating...

Gelonghui FinanceFeb 27 22:35

Express News | The concept of brain-computer interface became active in the afternoon, with Botuo Bio rising over 10%.

BreakingsFeb 13 14:13

Express News | Biotop Biotechnology and others have established a new brain-computer equity investment fund.

BreakingsFeb 12 10:48

Express News | The brain-computer interface sector of the A-share market rebounded in the closing session, with Aipeng Medical experiencing a short-term surge of over 4%. Other stocks such as Innovation Medical, Botuo Bio, Kefu Medical, and Saili Medical also followed w

BreakingsFeb 5 14:37

China Merchants Securities: Significant domestic policy support expected in 2025, with the brain-computer interface industry approaching a critical tipping point.

The scale of the Chinese market has grown rapidly, reaching 17.3 billion yuan in 2023, with its global share increasing to 12.5%. Driven by policies, demand, and an innovation system, the future holds broad prospects.

Zhitong FinanceJan 30 10:15